Contact Information

37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG

We Are Available 24/ 7. Call Now.

Fintel reports that on April 7, 2023,
Raymond James
maintained
coverage of LumiraDx (NASDAQ:LMDX) with
a Outperform recommendation.

Analyst Price Forecast Suggests 242.73% Upside

As of April 6, 2023,
the average one-year price target for LumiraDx is $2.13.
The forecasts range from a low of $0.86 to a high of $4.83.
The average price target represents an increase of 242.73% from its latest reported closing price of $0.62.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for LumiraDx
is $208MM, a decrease of 18.34%.

The projected annual non-GAAP EPS
is -$0.62.

What are Other Shareholders Doing?

LMDX / LumiraDx Ltd Shares Held by Institutions

Mariner
holds 30K shares
representing 0.01% ownership of the company.

No change in the last quarter.

Millennium Management
holds 25K shares
representing 0.01% ownership of the company.

In it’s prior filing, the firm reported owning 23K shares, representing
an increase
of 7.87%.

The firm

increased

its portfolio allocation in LMDX by 19,351.38% over the last quarter.

Cwm
holds 1K shares
representing 0.00% ownership of the company.

No change in the last quarter.

BDO Wealth Advisors
holds 161K shares
representing 0.05% ownership of the company.

No change in the last quarter.

Renaissance Technologies
holds 20K shares
representing 0.01% ownership of the company.

In it’s prior filing, the firm reported owning 49K shares, representing
a decrease
of 146.23%.

The firm

decreased

its portfolio allocation in LMDX by 65.18% over the last quarter.

What is the Fund Sentiment?

There are 46 funds or institutions reporting positions in LumiraDx.

This is a decrease
of
2
owner(s) or 4.17% in the last quarter.

Average portfolio weight of all funds dedicated to LMDX is 0.26%,
a decrease
of 21.17%.

Total shares owned by institutions decreased
in the last three months by 8.09% to 32,797K shares.

See all LumiraDx regulatory filings.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link

Share:

administrator

Leave a Reply

Your email address will not be published. Required fields are marked *